Biovac
Strategic Partnerships

Tech-Transfer Ecosystem

Global pharmaceutical partnerships integrated through Biovac's continental manufacturing hub in Cape Town. From biotherapeutics to sterile filling — verified, auditable, compliant.

Network

Global Supply-Chain Integration

Technology transfer partnerships with global pharmaceutical leaders, routed through the Cape Town manufacturing hub.

PFE

Pfizer Inc.

mRNA Technology Transfer · USA

COVID-19 vaccine fill-and-finish for African Union. mRNA technology transfer. 100M+ annual doses.

mRNA Technology Transfer
BVC

Biovac

Cape Town Manufacturing Hub

200,000L continental vaccine manufacturing facility. SAHPRA & FDA aligned. Full tech-transfer integration.

200,000L Total Capacity
SNY

Sanofi Pasteur

Hexavalent & IPV · France

Fully liquid hexavalent and IPV vaccine technology transfer. Established supply partnership for paediatric immunisation.

Hexavalent & IPV
SAHPRA GMP
PIC/S Annex 16
WHO Prequalification
FDA cGMP Reliance
EMA Reliance Pathway
POPIA Compliant
GAMP-5 Secure by Design

Immutable Audit Interface

Zero-trust edge architecture ensuring absolute data integrity for SAHPRA GMP submissions, WHO Prequalification documentation, and PIC/S Annex 11 compliance. Serverless design eliminates the shared-infrastructure attack surface inherent in legacy CMS architectures — which recorded 11,334 vulnerabilities in the current fiscal year alone. POPIA Section 19 compliant and GAMP-5 "secure by design" by architecture, not configuration. Every batch record and deviation is cryptographically hashed and immutable (Annex 11 aligned).

Live
Record ID Batch Document Type Timestamp Status SHA-256
BR-2026-00142 BVC-HEX-001-B08 Batch Record Nov 15, 09:23 ✓ Released a7f2c9e3...8b1d
QA-2026-00089 BVC-HEX-001-B08 QA Approval Nov 14, 16:45 ✓ Approved 3e91d4b7...2f6a
DEV-2026-00231 BVC-HEX-001-B08 Deviation Report Nov 13, 11:02 ◉ Resolved 8b4f7a21...c3e8
CC-2026-00067 BVC-PCV-013-A12 Change Control Nov 12, 08:15 ✓ Effective c2e6b19f...a4d7
BR-2026-00141 BVC-PCV-013-A12 Batch Record Nov 11, 14:38 ✓ Released 5d9a8342...e1b9
QA-2026-00088 BVC-OCV-001-A11 QA Approval Nov 10, 10:22 ● Under Review pending
Engagement

Partnership Models

Flexible partnership structures designed to meet your strategic objectives and accelerate your pipeline.

Model A

CDMO Services

Leverage our facilities and expert teams for process development, clinical supply, and commercial-scale biomanufacturing.

Inquire about CDMO
Model B

Strategic Alliances

Collaborate on co-development of novel biologics and vaccines from late-stage research through regulatory approval.

Propose an Alliance
Model C

Technology & Innovation

Engage on technology in-licensing or out-licensing opportunities to accelerate next-generation therapies.

Discuss Technology

Explore Partnership Opportunities

Join our growing ecosystem of global pharmaceutical partners and help build Africa's vaccine manufacturing capability.